<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>The latest update is out from Evotec AG ( (EVO) ). Evotec SE, a Germany-based life science and drug discovery specialist, has built proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modelling, alongside its Just – Evotec Biologics unit for biologics development and manufacturing. The company maintains a portfolio of more than 100 largely co-owned R&amp;D assets with a focus on oncology, cardiovascular and metabolic diseases, neurology and immunology. On April 29, 2026, Evotec announced the nomination of Dr. Wolfgang Hofmann as an independent member of its Supervisory Board, to be voted on at the Annual General Meeting scheduled for June 11, 2026. The AGM will also consider the previously announced nomination of Dieter Weinand as Supervisory Board Chairman and a proposal to expand the Supervisory Board from six to seven members, moves aimed at strengthening governance and supporting the company’s ongoing transformation. The company simultaneously disclosed a cooperation agreement with major shareholder MAK Capital Fund LP, following what both sides described as constructive discussions. The pact, under which MAK Capital has agreed to customary voting and cooperation commitments, underscores Evotec’s emphasis on active shareholder engagement and is intended to bolster long-term value creation and governance stability for investors. The most recent analyst rating on (EVO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page. Spark’s Take on EVO Stock According to Spark, TipRanks’ AI Analyst, EVO is a Neutral. The score is held down primarily by weak financial performance (persistent losses and negative free cash flow) and bearish longer-term technicals (below key moving averages, negative MACD). The earnings call adds partial support via cost-savings progress, strong biologics performance, and liquidity, but 2026 transition-year guidance and D&amp;PD weakness temper the outlook; valuation is also constrained by negative earnings and no dividend yield. To see Spark’s full report on EVO stock, click here. More about Evotec AG Evotec SE is a global life science company focused on drug discovery and development, integrating AI-driven innovation and advanced technologies to accelerate the path from concept to cure. The company offers services across small molecules, biologics, cell therapies and related modalities, working with all Top 20 pharma companies, more than 800 biotechs and academic partners, and operates over 4,500 staff across Europe and the U.S. Average Trading Volume: 157,835 Technical Sentiment Signal: Strong Sell Current Market Cap: $1.04B For an in-depth examination of EVO stock, go to TipRanks’ Overview page.</div>

LABU

IBBQ

SBIO

Evotec AG has announced the nomination of Dr. Wolfgang Hofmann to its Supervisory Board, with a vote scheduled for June 11, 2026. The company aims to strengthen governance by expanding the board from six to seven members and has entered a cooperation agreement with major shareholder MAK Capital Fund LP. This agreement emphasizes active shareholder engagement to enhance long-term value and governance stability. Despite a recent analyst rating of 'Buy' for EVO stock, concerns about financial performance and technical indicators persist, leading to a neutral outlook from analysts.

Tip Ranks

Evotec SE

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Evotec Strengthens Supervisory Board and Strikes Governance Pact With MAK Capital